Rosine Guimbaud
AuthID: R-00F-GS6
1
TÃTULO: First European phase II trial of intravenous (iv) cetuximab (Cet) and hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil and oxaliplatin in patients with unresectable liver metastases from wt KRAS colorectal cancer (CRC) after systemic therapy failure (OPTILIV, NCT00852228)
AUTORES: Francis Levi; Michel Ducreux; Mohamed Hebbar; Philippe Rougier; Focan, CNJ; Rosine Guimbaud; Carlos Carvalho; Salvatore Tumolo; Pasquale F Innominato; Yves Ajavon; Denis Castaing; Thierry De Baere; Abdoulaye Karaboue; Celine Lepere; Valerie Boige; Laetitia Proux; Rene Adam; Mohamed Bouchahda;
PUBLICAÇÃO: 2012, FONTE: 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 30, NÚMERO: 15
AUTORES: Francis Levi; Michel Ducreux; Mohamed Hebbar; Philippe Rougier; Focan, CNJ; Rosine Guimbaud; Carlos Carvalho; Salvatore Tumolo; Pasquale F Innominato; Yves Ajavon; Denis Castaing; Thierry De Baere; Abdoulaye Karaboue; Celine Lepere; Valerie Boige; Laetitia Proux; Rene Adam; Mohamed Bouchahda;
PUBLICAÇÃO: 2012, FONTE: 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 30, NÚMERO: 15
INDEXADO EM: 
WOS
WOS